Clinical Trials Sponsored by EMO Biomedicine Corporation

Total 14 results

EMO Biomedicine Corporation
Far Eastern Memorial Hospital

Completed

Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stromal Cell Product (RegStem)

Osteoarthritis,Knee

Taiwan
EMO Biomedicine Corporation
Far Eastern Memorial Hospital

Completed

Large-scale ex Vivo Expansion and Characterization of Two Kinds of MSC From Knee for Clinical Application

Knee Injuries

Taiwan
Chin-Hung Chang
EMO Biomedicine Corporation

Unknown

Large-scale Expansion and Characterization of Mesenchymal Stem Cells for Clinical Application

Knee Injuries

Taiwan
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Completed

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Canada
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Completed

A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment

Healthy Volunteers | Hepatic Impairment

United States
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Completed

A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects

Healthy Volunteers

United States
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Available

Individual Patient Compassionate Use of Fedratinib

Myelofibrosis

United States
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Completed

Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects

Healthy Volunteers

United States
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Completed

Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin

Healthy Volunteers

United States
Denver Health and Hospital Authority
Microsoft Corporation; EMC Consulting

Completed

Chronic Care Management/Patient Relationship Management Proof of Concept

Diabetes Mellitus

United States
Stichting European Myeloma Network
Celgene Corporation; Healt Data Specialists - HeaDS (CRO); EMN Research Italy...

Active, not recruiting

Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients

Multiple Myeloma

France, Greece, Italy, Netherlands
Hamilton Health Sciences Corporation
Canadian Institutes of Health Research (CIHR); Population Health Research Institute and other collaborators

Not yet recruiting

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy (TaRGET)

Arrhythmogenic Right Ventricular Cardiomyopathy | Arrhythmogenic Cardiomyopathy

Canada
Paris Translational Research Center for Organ Transplantation
Agence de La Biomédecine; Eurotransplant; United Network for Organ Sharing; Deutsche... and other collaborators

Unknown

COVID-19 Pandemic and Worldwide Organ Procurement (COVID)

COVID-19

France

Clinical Trials Sponsored by EMO Biomedicine Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations